Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Artax Biopharma

Request full access

Biopharmaceutical company that develops new therapies for autoimmune and inflammatory diseases

Cambridge, United StatesFounded 2013Biotech & Life Sciences

About Artax Biopharma

Artax Biopharma, Inc. is a clinical-stage biotechnology firm established in 2013, with its headquarters in Cambridge, Massachusetts. The company was co-founded by Dr. Damià Tormo and Dr. Balbino Alarcón. Dr. Tormo, who also served as the initial CEO, has an extensive background in the biopharmaceutical industry, venture capital, and has founded several other biotech companies. His scientific journey began as a researcher at institutions like the University of Michigan and the Spanish National Cancer Center (CNIO). Dr. Alarcón is a distinguished immunologist whose research on T cell receptor (TCR) signaling at the National Research Council of Spain (CSIC) provided the foundational science for Artax. His lab's discovery that the TCR changes conformation upon stimulation, exposing a site that recruits the Nck protein, was a pivotal breakthrough that underpins the company's therapeutic approach.

Artax Biopharma is focused on developing a new class of oral small molecules for the treatment of T cell-driven autoimmune and inflammatory diseases. The company operates in the biopharmaceutical market, aiming to provide therapies for conditions such as psoriasis, atopic dermatitis, and rheumatoid arthritis. Its business model centers on the research, development, and eventual commercialization of its proprietary drug candidates. The company generates capital through financing rounds, having secured significant funding from investors including Eli Lilly and Company, Advent Life Sciences, Columbus Venture Partners, and Sound Bioventures.

The company's lead product candidate is AX-158, a first-in-class oral small molecule designed to modulate the immune system without causing general immunosuppression. AX-158 works by selectively targeting and inhibiting the interaction between the T cell receptor (TCR) and the Nck protein, a key signaling amplifier in T cell activation. Dysregulated TCR signaling is a root cause of many autoimmune diseases where the immune system mistakenly attacks the body's own tissues. By blocking the Nck interaction, AX-158 aims to recalibrate T cell responses, preventing self-activation while preserving the immune system's ability to fight infections. This targeted immunomodulation is a key differentiator from many existing autoimmune therapies that broadly suppress the immune system. AX-158 has completed Phase 1 trials and a Phase 2a study in psoriasis, demonstrating a favorable safety profile and providing proof of mechanism. The company plans to initiate further Phase 2 trials for atopic dermatitis and rheumatoid arthritis.

Source: Dealroom company data

At a glance

Status
Operational
Employees
13
Open positions
None listed
Dealroom signal
72.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Medical & Healthcare, Autoimmune, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
CONVERTIBLEOther financing Aug 2024 $8M — Eli Lilly · Belinda Termeer · Sound Bioventures · Columbus Venture Partners ↗
LATE VCOther financing May 2022 $26M $104M Belinda Termeer · Sound Bioventures · Columbus Venture Partners · Advent Life Sciences ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Artax Biopharma website traffic

Latest recorded traffic for Artax Biopharma is 3.5K monthly website visits, up 25% over the last three months. Artax Biopharma's team grew 0% over the past year.

Latest monthly visits3.5K 3-month web change+25% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Artax Biopharma in the Cambridge ecosystem

Live from Dealroom

The Artax Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Lysosomal Therapeutics
  • Advent Life Sciences
  • Columbus Venture Partners
  • Eli Lilly

Series B and later2 investors entered at this stage

  • Sound Bioventures
  • Belinda Termeer

Other known investors1 additional known investor

  • Spanish National Research Council
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States45.5%
🇪🇸 Spain27.3%
🇬🇧 United Kingdom9.1%
🇳🇱 Netherlands9.1%
🇸🇪 Sweden9.1%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Artax Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Artax Biopharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.